Biota Pharmaceuticals to Present at the 27th Annual Roth Conference

ATLANTA, March 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that Biota CEO & President Joseph Patti will present a corporate overview at the 27th Annual ROTH Conference. The presentation will take place on Monday, March 9, 2015 at 11:00 a.m. PDT at the Ritz Carlton Hotel in Dana Point, CA.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at or at A replay of the webcast will be archived for 30 days following the presentation.

About Biota Pharmaceuticals, Inc.

Biota Pharmaceuticals, Inc. is a company focused on the discovery and development of products to treat serious viral respiratory infectious diseases. The Company currently has two late-stage product candidates: (i) laninamivir octanoate, which is being developed as a one-time, inhaled treatment for influenza A and B infections; and (ii) vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses in development for the treatment of human rhinovirus infected patients with underlying respiratory illnesses, such as moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD). The Company is also conducting IND-enabling studies with BTA-C585, an orally bioavailable F protein inhibitor, in development for the treatment of respiratory syncytial virus infections. For additional information about the Company, please visit

Biota is a registered trademark of Biota Pharmaceuticals, Inc.

CONTACT: Joseph M. Patti, PhD President and Chief Executive Officer (678) 221-3351 Sarah McCabe Stern Investor Relations, Inc. (212) 362-1200

Source:Biota Pharmaceuticals, Inc.